Anika Therapeutics, Inc. (ANIK) vs Inhibikase Therapeutics, Inc. (IKT)
A side-by-side comparison of Anika Therapeutics, Inc. and Inhibikase Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ANIK
Anika Therapeutics, Inc.
$19.12HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
IKT
Inhibikase Therapeutics, Inc.
$1.98HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — ANIK vs IKT
growth of $100 · dividends reinvested · last 6yANIK -48.7% (-10.5%/yr)IKT -96.6% (-43.2%/yr)ANIK compounded faster over this window
Log scale — wide-divergence pair
ANIK IKT
ANIK vs IKT: by the numbers
- •IKT is the larger company ($261M vs $256M market cap).
- •Both run net losses; IKT's is the smaller (0.00% vs -3.14% net margin).
Metrics side by side
Valuation
| Metric | ANIK | IKT |
|---|---|---|
| Forward P/E | 18.21 | N/A |
| P/S ratio | 2.12 | N/A |
| P/B ratio | 1.86 | 1.71 |
| EV / EBITDA | 473.06 | N/A |
| FCF yield | 0.22% | N/A |
Profitability
| Metric | ANIK | IKT |
|---|---|---|
| Gross margin | 62.16% | 0.00% |
| Operating margin | -4.24% | 0.00% |
| Net margin | -3.14% | 0.00% |
| ROE | -2.76% | -39.55% |
| ROIC | -3.17% | -42.92% |
Growth (annualized)
| Metric | ANIK | IKT |
|---|---|---|
| Revenue CAGR (5Y) | -2.48% | N/A |
| FCF CAGR (5Y) | -39.38% | N/A |
| Total return CAGR (5Y) | -13.40% | -29.10% |
Frequently asked
- How have ANIK and IKT total returns compared?
- Over the past 5 years, ANIK delivered -13.40% and IKT delivered -29.10% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.